FDA-cleared profile

Volpara Imaging Software

Volpara Health Technologies Limited · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.

Clinical role
Automated volumetric measurement with adjunctive density and quality-assurance reporting.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.
  • Who uses it?Intended users: Healthcare professionals; the final density-category assessment is made by an MQSA-qualified interpreting physician.
  • What does the software produce?Output: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
  • What is its most important limitation?Key limitation: Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.

Clinical takeaway. Clinical role: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.

Evidence takeaway. Evidence from the reviewed source record: Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Automated volumetric measurement with adjunctive density and quality-assurance reporting.
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Post-processing following mammographic or digital breast tomosynthesis screening examinations.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Healthcare professionals; the final density-category assessment is made by an MQSA-qualified interpreting physician.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.
  • Exact FDA submission
  • Checked 2026-09-05

The baseline ACR shorthand Scanner manufacturers: All is narrowed to the FDA summary's supported input configurations; universal scanner support is not inferred.

Evidence summary
Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.
  • Product family
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.
  • Public source
  • Product family
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

The exact summary does not report disease-detection sensitivity; the family epidemiology study is not a software accuracy validation.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No disease-detection specificity for version 3.2 was established.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Volpara Imaging Software 3.2 Special 510(k) verification and validation

  • DesignSoftware unit and integration validation with repeated predicate tests for compatibility and software modifications.
  • PopulationSoftware verification dataset; clinical cohort size not reported in the summary.
  • Scopeexact submission
  • Tested versionVolpara Imaging Software 3.2
  • IndependenceIndependence not established

K211279

Cadmium and volumetric mammographic density: A cross-sectional study in Polish women

  • DesignCross-sectional epidemiology study relating urinary cadmium to volumetric mammographic density.
  • Population517 women aged 40-60 undergoing screening mammography in Lodz, Poland; raw CC and MLO images analyzed with Volpara.
  • Scopeproduct family
  • Tested versionVolpara Imaging Software; version not specified in reviewed abstract
  • Samplen=517
  • IndependenceIndependence not established

PMID:32433664 · DOI:10.1371/journal.pone.0233369

Abstract reviewed. This is use of a measurement tool, not a sensitivity/specificity study or validation of version 3.2. No software-outcome claim is extracted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Receives raw mammography/DBT data and generates a DICOM Secondary Capture scorecard, density maps and a DICOM Mammography CAD Structured Report; DICOM 2016 testing is described.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

  3. AI processing

    Source context, not route validation: The exact summary describes a Microsoft Azure-connected off-the-shelf virtual appliance and lists Windows/Linux operating environments.

    Scope: Exact FDA submission. Refines the baseline On-premise label. The summary does not fully resolve hosting region, what crosses the Azure connection or current commercial topology.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

  4. Returned objects

    Source context, not route validation: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact summary describes a Microsoft Azure-connected off-the-shelf virtual appliance and lists Windows/Linux operating environments.
  • Exact FDA submission
  • Checked 2026-09-05

Refines the baseline On-premise label. The summary does not fully resolve hosting region, what crosses the Azure connection or current commercial topology.

Integration
Receives raw mammography/DBT data and generates a DICOM Secondary Capture scorecard, density maps and a DICOM Mammography CAD Structured Report; DICOM 2016 testing is described.
  • Exact FDA submission
  • Checked 2026-09-05

Current Scorecard family context

The official Scorecard page combines density and risk information and states that Tyrer-Cuzick 8 risk modeling requires additional software purchase and is not available in all countries.

product family · checked 2026-09-05

Does not add risk modeling to the cleared indications of Volpara Imaging Software 3.2.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211279
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-07-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
10Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored titles screened: 35913368 (ionizing radiation) and 34524273 (cigarette smoking) are density epidemiology leads without exact-version linkage in metadata; not promoted. PMID 32433664 abstract reviewed live and retained only as contextual product-family use. No trials stored. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, peer reviewed publication, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-05 - Exact product version

    Checked 2026-10-25: the vendor-published US Master License and Services Agreement (v02-2024) says fees are set per customer in a Quotation, with no list price. The Scorecard product page already on file establishes no price. Federal award records found were aggregator listings, not a price for this cleared version. No price is stated.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Volpara Imaging Software reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact product version

    The summary's description of a secure virtual host does not establish a current scoped security attestation or Azure data flow and retention controls.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact product version

    The physician qualification is known; a version 3.2 training syllabus, duration and competency process were not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact product version

    Density sanity checking is described for 3.2, but a site monitoring service or update acceptance program was not established. Editorial questions: confirm raw-image routing, supported paddles and correct scorecard/patient matching.

10 sources - 3 history items

Source ledger

  1. K211279 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Volpara Imaging Software model card (K211279)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Volpara Imaging Software 3.2: K211279 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  8. Volpara Scorecard product page

    Volpara Health - Accessed 2026-09-05

    Scope: product_family_context

  9. Cadmium and volumetric mammographic density: A cross-sectional study in Polish women

    PLOS ONE / PubMed - Published 2020-05-20 - Accessed 2026-09-05

    Scope: product_family_study_context

  10. Volpara Health Master License and Services Agreement (US, v02-2024)

    Lunit / Volpara Health, Inc. - Accessed 2026-10-25

    Scope: pricing

Research history

  1. K211279 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history